[
    {
        "file_name": "Array BioPharma Inc. - LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.50 \"Product\" means shall mean any pharmaceutical product containing, as an active ingredient, one or more of Binimetinib or Encorafenib, including, without limitation, any Combination Product.",
                "changed_text": "1.50 \"Product\" means shall mean any pharmaceutical product containing, as an active ingredient, only Binimetinib, excluding any Combination Product.",
                "explanation": "The original definition included any product containing Binimetinib or Encorafenib, including Combination Products. The modified version explicitly excludes Combination Products, contradicting the original intent and creating ambiguity.",
                "location": "1.50"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.57 \"Subcontractor\" means any Third Party to which a Party or its Affiliate may subcontract the performance of any activities undertaken in accordance with this Agreement, provided that for clarity any entity which is involved in the selling of Products and is responsible for booking sales of Products shall not be included within this definition.",
                "changed_text": "1.57 \"Subcontractor\" means any Third Party to which a Party or its Affiliate may subcontract the performance of any activities undertaken in accordance with this Agreement, including any entity which is involved in the selling of Products and is responsible for booking sales of Products.",
                "explanation": "The original definition explicitly excluded entities involved in selling Products. The modified definition now includes them, creating a direct contradiction and uncertainty about the scope of subcontracting allowed.",
                "location": "1.57"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.14  \"Development\" or \"Develop\" means non-clinical and clinical research and drug development activities, including toxicology, pharmacology, statistical analysis, Clinical Studies (including pre- and post-approval studies, Post-Approval Marketing Clinical Studies and Investigator Sponsored Clinical Studies), stability testing, formulation, process development, quality assurance/control development, regulatory affairs, and regulatory activities pertaining to designing and carrying out Clinical Studies and obtaining and maintaining Marketing Approvals (including pre-marketing activities but excluding regulatory activities directed to obtaining Pricing and Reimbursement Approvals).",
                "changed_text": "1.14  \"Development\" or \"Develop\" means only non-clinical and clinical research and drug development activities directly associated with obtaining pricing and reimbursement approvals.",
                "explanation": "The original definition includes a broad range of activities. The modified version extremely limits Development to only those activities associated with obtaining pricing and reimbursement. Creates tension about the definition and enforcement.",
                "location": "1.14"
            }
        ]
    }
]